Rituxan
Jun 20, 2017
J&J nabs; Clovis plots Rubraca; Novartis scores EU approval; Seattle Genetics stops trials
Johnson & Johnson nabs another combo approval for myeloma star Darzalex Late last year, Johnson & Johnson widened Darzalex’s reach with some combo approvals. And now, it’s adding to that roster. The medication has snagged a green light for use in tandem with chemo drug dexamethasone and Celgene’s Pomalyst fo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
